阿替利珠单克隆抗体联合贝伐珠单克隆抗体一线治疗不可切除肝细胞癌的临床疗效  

Clinical efficacy of atezolizumab plus bevacizumab for first‐line treatment of unresectable hepatocellular carcinoma

作　　者：胡晓云[1] 臧梦雅 李祺[1] 袁国盛 李榕[1] 陈锦章[1] Hu Xiaoyun;Zang Mengya;Li Qi;Yuan Guosheng;Li Rong;Chen Jinzhang(State Key Laboratory of Organ Failure Research,Guangdong Provincial Key Laboratory of Viral Hepatitis Research,Department of Infectious Diseases,Department of Liver Tumor Diseases,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China)

机构地区：[1]器官衰竭防治国家重点实验室,广东省病毒性肝炎研究重点实验室,南方医科大学南方医院感染内科,南方医科大学南方医院肝脏肿瘤中心,广州510515

出　　处：《中华消化外科杂志》2021年第S02期20-24,共5页Chinese Journal of Digestive Surgery

基　　金：南方医科大学南方医院院长基金(2008C006)

摘　　要：晚期肝癌治疗手段有限、预后差。过去10余年,仅2个酪氨酸激酶抑制剂靶向药物在全世界获批用于晚期肝癌一线治疗。2020年,阿替利珠单克隆抗体+贝伐珠单克隆抗体在全世界获批用于晚期肝癌一线治疗。作为首个优于索拉非尼的全新疗法,其安全性良好、病人生命质量较高。笔者报道1例中国肝癌分期Ⅲb期肝癌病人行阿替利珠单克隆抗体+贝伐珠单克隆抗体治疗的临床经验,其研究结果显示:病人治疗后<3个月肿瘤出现部分缓解,疾病无进展生存时间>26个月,治疗过程中不良事件可控,耐受性良好,体能状态维持良好。Advanced hepatocellular carcinoma(HCC)has limited treatment options and poor prognosis.Only two tyrosine kinase inhibitors have been approved as single agents for firstline treatment over the last decade.In 2020,atezolizumab combined with bevacizumab was approved for first‐line treatment of advanced HCC.As the first brand‐new therapy to surpass sorafenib,atezolizumab combined with bevacizumab showed good safety and life quality in patients.The authors introduced the diagnosis and treatment of a China Liver Cancer StagingⅢb HCC patient receiving atezolizumab combined with bevacizumab,in order to provide references for patient management.

关 键 词：肝肿瘤 原发性 免疫治疗 靶向治疗 阿替利珠单克隆抗体 贝伐珠单克隆抗体 临床疗效 安全性 

分 类 号：R735.7[医药卫生—肿瘤]